Addition of daratumumab to bortezomib and dexamethasone in patients with relapsed or refractory shows promising results in a phase III trialMyelomaOctober 13, 2016
SURVEY: Reasonable agreements between pharmaceutical companies and patient advocatesMPEOctober 6, 2016
